2nd Annual TGF-β for Immuno-Oncology Drug Development

Tuesday, January 25th – Thursday, January 27th

Digital Event:
Click here for access

 Overview:

Outcome’s Dr. John Armstrong will be providing An Overview of the TGF-β IO Market including:

  • Current approaches in the TGF-β IO market
  • Recent M&A, equity financing, and strategic partnership transactions in the TGF- β IO market
  • How to position your company, team, and asset for a successful entry into the TGF-β IO market

For more information, please contact jarmstrong@outcomecapital.com

News

Outcome Capital Launches the First Dedicated Ophthalmology Practice to Address the World’s Leading Cause of Disability

Appoints Paul Ryb Managing Director to Lead Firm’s Expansion BOSTON–(BUSINESS WIRE)-July 8, 2025-Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Paul Ryb has been appointed Managing Director and will lead the firm’s dedicated ophthalmology practice, providing strategic guidance, transactional support, and advisory services to clients […]

Read More
Resources

Outcome Capital Life Science Market Pulse, May 2025

Outcome Capital Life Science Market Pulse May 2025 Click to view our LifeSciences Pulse Newsletter

Download

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Contact Us

  • Boston

    20 Custom House St, Suite 1200, Boston, MA 02110
    (617) 431-2278

© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC

Business Continuity Plan | Privacy Policy | Regulation Best Interest

Built by Metropolis